Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate-Reference-Cited by-同舟云学术

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate

Author:

Gertz M A,Lacy M Q,Dispenzieri A,Ansell S M,Elliott M A,Gastineau D A,Inwards D J,Micallef I N M,Porrata L F,Tefferi A,Litzow M R

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

Reference34 articles.

2. Kyle RA . Clinical aspects of multiple myeloma and related disorders including amyloidosis. Pathol Biol (Paris) 1999; 47: 148–157.

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Hematopoietic Cell Transplantation in Light Chain Amyloidosis;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

3. Stem Cell Transplant for Plasma Cell Dyscrasias;Basics of Hematopoietic Stem Cell Transplant;2023

4. Treatment of AL Amyloidosis;Amyloidosis and Fabry Disease;2023